MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/190/0.1/16.01.26 | Market Closed - Börse Stuttgart 12:13:48 2024-05-31 EDT | ||
| 0.91 EUR | +7.06% |
|
| Current month | -3.19% | ||
| 1 month | -3.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.91 | +7.06% |
| 24-05-30 | 0.85 | -.--% |
| 24-05-29 | 0.85 | -5.56% |
| 24-05-28 | 0.9 | +1.12% |
| 24-05-27 | 0.89 | -6.32% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 12:13 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME9ZMS |
| ISIN | DE000ME9ZMS4 |
| Date issued | 2024-03-11 |
| Strike | 190 $ |
| Maturity | 2026-01-16 (595 Days) |
| Parity | 10 : 1 |
| Emission price | 1.35 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.26 € |
|---|---|
| Lowest since issue | 0.72 € |
| Spread | 0.01 € |
| Spread % | 1.08% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
